Welcome to our dedicated page for Cellebrite Di news (Ticker: CLBTW), a resource for investors and traders seeking the latest updates and insights on Cellebrite Di stock.
Cellebrite Di Ltd (NASDAQ: CLBTW) delivers critical Digital Intelligence solutions for modern investigative challenges. This news hub provides stakeholders with essential updates about the company’s technological advancements, regulatory compliance, and market positioning.
Access consolidated information on product launches, partnership announcements, and financial disclosures relevant to CLBTW’s role in digital forensics and corporate investigations. Our curated collection serves investors and professionals needing to monitor developments in SaaS-based investigative tools, eDiscovery innovations, and cybersecurity capabilities.
Key updates include earnings reports, leadership changes, and technology patents across Cellebrite’s Case-to-Closure platform. All content undergoes strict verification to ensure accuracy and relevance for decision-makers in both public sector and corporate environments.
Bookmark this page for streamlined access to CLBTW’s latest developments in legally compliant data analysis solutions. Regularly updated to reflect the company’s progress in addressing evolving digital security demands.
Cellebrite (NASDAQ: CLBT) announced the general availability of Generative AI (GenAI) capabilities within Guardian, its SaaS-based evidence management solution. The new features help public safety agencies process digital evidence more efficiently by:
- Summarizing chat threads from smartphones containing an average of 60,000 text messages
- Providing relationship insights for investigating complex crime networks
- Analyzing browsing history by breaking down complex URLs and contextualizing searches
Detective Sergeant Aaron Osman from Susquehanna Township Police Department reported that the GenAI capabilities helped translate and summarize chats between suspects, leading to the discovery of an international organized crime ring involved in porch package thefts. According to Cellebrite's industry survey, while 30% of respondents noticed increased AI-related criminal activity, 64% believe AI technology can help reduce crime.
Cellebrite (NASDAQ: CLBT), a global leader in Digital Investigative solutions, has announced it will release its fourth-quarter and fiscal year 2024 financial results before market open on Thursday, February 13, 2025.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the Q4 2024 results and provide outlook for 2025. Historical financial tables and supplemental data will be made available on the company's investor relations website.
Cellebrite (NASDAQ: CLBT), a global leader in digital investigative solutions, has announced its participation in the upcoming Needham & Company 27th Annual Growth Conference.
The event will take place on January 14, 2025, with Cellebrite's presentation scheduled for 8:45 a.m. ET. The presentation format will be a Fireside Chat and can be accessed via the event URL: https://investors.cellebrite.com/events/event-details/needham-co-27th-annual-growth-conference.
Key executives representing Cellebrite at the conference will be Dana Gerner, Chief Financial Officer, and Andrew Kramer, Vice President, Investor Relations.
Cellebrite (NASDAQ: CLBT), a global leader in Digital Investigative solutions, announced key updates to its Board of Directors to bolster the company's growth in 2025 and beyond. As of January 1, 2025, Thomas E. Hogan has been confirmed as interim CEO, while maintaining his role on the Board, with plans to revert to chairman once a new CEO is appointed. Adam H. Clammer, Managing Partner of True Wind Capital Management, has taken on the role of board chairman, adhering to best practices in board governance by separating the CEO and board chair duties.
Additionally, Michael D. Capellas, with extensive leadership experience across top technology companies, joins Cellebrite's Board as a Class II director and the new lead independent director, replacing Adam Clammer. Capellas's notable roles include CEO positions at VCE, First Data , MCI, Compaq Computer , and President at Hewlett-Packard.
Capellas expressed enthusiasm for joining Cellebrite, highlighting his commitment to justice, safety, and security, and his alignment with the company's mission to combat child exploitation and trafficking.
Cellebrite (NASDAQ: CLBT), a global leader in Digital Investigative solutions, announced its participation in the upcoming UBS Global Technology and AI Conference. The company will participate in a fireside chat on December 3, 2024, at 4:55 p.m. ET. Key executives attending include Thomas Hogan (executive chairman), Dana Gerner (CFO), and Andrew Kramer (VP of investor relations).
Cellebrite (Nasdaq: CLBT) and Relativity announced the general availability of Cellebrite's mobile collection solutions integration into RelativityOne platform. The integration enables faster and more efficient mobile data management in legal processes. Following a successful Advanced Access program in July 2024, users reported significant efficiency gains, reducing mobile device data collection time to just over an hour compared to previous days or weeks. The integration allows remote mobile device collections to be fully orchestrated within RelativityOne, including custodian notification and automatic data transfer. According to Cellebrite's 2024 Industry Trends survey, 97% of eDiscovery cases now involve at least one mobile device.
Cellebrite reported strong Q3 2024 financial results, achieving a significant milestone with quarterly revenue exceeding $100 million for the first time. Revenue reached $106.9 million, up 27% year-over-year, driven by 27% growth in subscription revenue to $93.4 million. The company's Annual Recurring Revenue (ARR) grew 26% to $370.8 million, with a net retention rate of 124%.
Key highlights include adjusted EBITDA of $31.3 million with a 29.3% margin. The company announced Pathfinder in the Cloud with AWS and received a patent for Remote Mobile Collection. Based on strong performance, Cellebrite increased its 2024 outlook for revenue to $397-401 million and adjusted EBITDA to $94-100 million, while raising the low end of its ARR target range to $390-400 million.
Cellebrite (NASDAQ: CLBT) announced that CEO Yossi Carmil will step down from his position and Board of Directors by December 31, 2024. Executive Chairman Thomas E. Hogan will serve as interim CEO while the company conducts a formal search for a new chief executive. Under Carmil's 19-year leadership, Cellebrite grew from 18 to over 1,100 employees, expanded to dozen offices worldwide, and serves approximately 7,000 customers in more than 100 countries. Notable achievements include taking the company public in 2021, transitioning to a subscription business model, and launching the AI-driven Case-to-Closure platform. The company's market valuation has doubled to approximately $4 billion since going public.
Cellebrite (NASDAQ: CLBT) reported strong Q3 2024 results, achieving a milestone of $106.9 million in quarterly revenue, up 27% year-over-year. Subscription revenue grew 27% to $93.4 million, while Annual Recurring Revenue (ARR) reached $370.8 million, up 26% year-over-year. The company reported an Adjusted EBITDA of $31.3 million with a 29.3% margin. Despite posting a GAAP net loss of $207.1 million, non-GAAP net income was $31.8 million. Based on strong performance, Cellebrite increased its 2024 outlook for revenue and adjusted EBITDA, raising the low end of the ARR target range to $390-400 million.
Cellebrite (NASDAQ: CLBT) announced Tim Tebow as the keynote speaker for their inaugural Case-to-Closure (C2C) User Summit scheduled for March 31-April 3, 2025, in Washington, D.C. The summit will gather digital investigation leaders to discuss industry trends and best practices. Tebow will address his foundation's global fight against human trafficking, aligning with Cellebrite's Operation Find Them All initiative. The event will feature over three dozen speakers covering various digital investigative topics, including notable case studies and technological developments. Attendees will have opportunities for networking, professional training, and knowledge expansion across different levels of the investigative process.
FAQ
What is the current stock price of Cellebrite Di (CLBTW)?
